Literature DB >> 31697337

Neuroendocrine Tumors-Less Well Known, Often Misunderstood, and Rapidly Growing in Incidence.

Aman Chauhan1, Elise Kohn2, Jaydira Del Rivero3.   

Abstract

Entities:  

Mesh：

Year:  2020        PMID： 31697337      PMCID： PMC9382718          DOI： 10.1001/jamaoncol.2019.4568

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   33.006


× No keyword cloud information.
  3 in total

1.  Patterns and Drivers of Costs for Neuroendocrine Tumor Care: A Comparative Population-Based Analysis.

Authors:  Julie Hallet; C H L Law; M Cheung; N Mittmann; N Liu; H D Fischer; S Singh
Journal:  Ann Surg Oncol       Date:  2017-07-10       Impact factor: 5.344

2.  Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States.

Authors:  Arvind Dasari; Chan Shen; Daniel Halperin; Bo Zhao; Shouhao Zhou; Ying Xu; Tina Shih; James C Yao
Journal:  JAMA Oncol       Date:  2017-10-01       Impact factor: 31.777

3.  Global burden of neuroendocrine tumors and changing incidence in Kentucky.

Authors:  Aman Chauhan; Qian Yu; Neha Ray; Zainab Farooqui; Bin Huang; Eric B Durbin; Thomas Tucker; Mark Evers; Susanne Arnold; Lowell B Anthony
Journal:  Oncotarget       Date:  2018-04-10
  3 in total
  10 in total

1.  The clinical and prognostic factors for biliary neuroendocrine neoplasm: a study based on the SEER database.

Authors:  Bo-Hao Zheng; Cheng Zhang; Wen-Ze Wan; Wen-Tao Sun; Xi Cheng; Xiao-Jian Ni; Xiao-Ling Ni; Tao Suo; Han Liu; Sheng Shen; Hou-Bao Liu
Journal:  BMC Surg       Date:  2022-06-29       Impact factor: 2.030

2.  Highly variable biodistribution of 68Ga labeled somatostatin analogues 68Ga-DOTA-NOC and 68Ga-DOTA-TATE in neuroendocrine tumors: clinical implications for somatostatin receptor directed PET/CT.

Authors:  Monica Cheng; Mark Tann
Journal:  Hepatobiliary Surg Nutr       Date:  2022-10       Impact factor: 8.265

Review 3.  Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences?

Authors:  Satya Das; Arvind Dasari
Journal:  Curr Oncol Rep       Date:  2021-03-14       Impact factor: 5.075

Review 4.  Somatostatin receptor radionuclide therapy in neuroendocrine tumors.

Authors:  Mintallah Haider; Satya Das; Taymeyah Al-Toubah; Eleonora Pelle; Ghassan El-Haddad; Jonathan Strosberg
Journal:  Endocr Relat Cancer       Date:  2021-03       Impact factor: 5.678

5.  A proof-of-concept methodology to validate the in situ visualization of residual disease using cancer-targeted molecular agents in fluorescence-guided surgery.

Authors:  Servando Hernandez Vargas; Christie Lin; Solmaz AghaAmiri; Julie Voss; Naruhiko Ikoma; Hop S Tran Cao; Sukhen C Ghosh; Adam J Uselmann; Ali Azhdarinia
Journal:  Proc SPIE Int Soc Opt Eng       Date:  2020-02-19

6.  Error in Figure.

Authors: 
Journal:  JAMA Oncol       Date:  2020-01-01       Impact factor: 33.006

7.  hPG80 (Circulating Progastrin), a Novel Blood-Based Biomarker for Detection of Poorly Differentiated Neuroendocrine Carcinoma and Well Differentiated Neuroendocrine Tumors.

Authors:  Aman Chauhan; Alexandre Prieur; Jill Kolesar; Susanne Arnold; Léa Payen; Younes Mahi; Berengere Vire; Madison Sands; B Mark Evers; Dominique Joubert; Lowell Anthony
Journal:  Cancers (Basel)       Date:  2022-02-09       Impact factor: 6.639

Review 8.  Efficacy of Immune Checkpoint Inhibitors against Advanced or Metastatic Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis.

Authors:  Eun-Joo Park; Hyo-Jung Park; Kyung-Won Kim; Chong-Hyun Suh; Changhoon Yoo; Young-Kwang Chae; Sree Harsha Tirumani; Nikhil H Ramaiya
Journal:  Cancers (Basel)       Date:  2022-02-04       Impact factor: 6.639

9.  Neuroendocrine Tumors: An Analysis of Prevalence, Incidence, and Survival in a Hospital-Based Study in Ecuador.

Authors:  Karime Montes Escobar; Jose Luis Vicente-Villardon; Rosa Elisa Villacís Gonzalez; Paul Humberto Castillo Cordova; Johanna Mabel Sánchez Rodríguez; Melina De la Cruz-Velez; Aline Siteneski
Journal:  Healthcare (Basel)       Date:  2022-08-18

Review 10.  Novel therapeutics for patients with well-differentiated gastroenteropancreatic neuroendocrine tumors.

Authors:  Satya Das; Arvind Dasari
Journal:  Ther Adv Med Oncol       Date:  2021-05-21       Impact factor: 8.168
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.